$ANEB
Anebulo Pharmaceuticals, Inc.

2023 Q2 Form 10-Q Financial Statement

#000149315223016382 Filed on May 11, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.080M $1.775M $964.3K
YoY Change -10.55% 84.04% 245.51%
% of Gross Profit
Research & Development $1.420M $1.089M $915.4K
YoY Change 27.0% 19.01% 235.25%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $2.490M $2.864M $1.880M
YoY Change 7.07% 52.37% 240.43%
Operating Profit -$2.864M -$1.880M
YoY Change 52.37%
Interest Expense $90.00K $0.00
YoY Change 1127.83% -100.0%
% of Operating Profit
Other Income/Expense, Net -$90.00K $66.07K $3.150K
YoY Change 1860.78% 1997.46%
Pretax Income -$2.500M -$2.798M -$1.876M
YoY Change 7.63% 49.11% 237.6%
Income Tax
% Of Pretax Income
Net Earnings -$2.500M -$2.798M -$1.876M
YoY Change 7.63% 49.11% 237.6%
Net Earnings / Revenue
Basic Earnings Per Share -$0.11 -$0.08
Diluted Earnings Per Share -$0.10 -$0.11 -$80.38K
COMMON SHARES
Basic Shares Outstanding 25.63M shares 25.63M shares 23.34M shares
Diluted Shares Outstanding 25.63M shares

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $11.25M $14.16M $16.55M
YoY Change -22.67% -14.4% 400.37%
Cash & Equivalents $11.25M $14.16M $16.55M
Short-Term Investments
Other Short-Term Assets $420.0K $267.8K $700.7K
YoY Change -59.26% -61.78% 18.43%
Inventory
Prepaid Expenses $422.7K $267.8K
Receivables
Other Receivables
Total Short-Term Assets $11.67M $14.43M $17.25M
YoY Change -25.09% -16.33% 342.41%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $151.00 -$4.00 $0.00
YoY Change 15000.0% -100.0%
TOTAL ASSETS
Total Short-Term Assets $11.67M $14.43M $17.25M
Total Long-Term Assets $151.00 -$4.00 $0.00
Total Assets $11.67M $14.43M $17.25M
YoY Change -25.09% -16.33% 301.92%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $534.5K $570.9K $83.28K
YoY Change 40.36% 585.52% 1.52%
Accrued Expenses $534.3K $920.2K $2.500K
YoY Change 305.65% 36707.32% -98.82%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.070M $1.491M $85.78K
YoY Change 108.77% 1638.27% -70.74%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.070M $1.491M $85.78K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.069M $1.491M $85.78K
YoY Change 108.53% 1638.27% -99.2%
SHAREHOLDERS EQUITY
Retained Earnings -$57.20M -$54.70M
YoY Change 25.8%
Common Stock $25.63K $25.63K
YoY Change 9.81%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $10.60M $12.94M $17.16M
YoY Change
Total Liabilities & Shareholders Equity $11.67M $14.43M $17.25M
YoY Change -25.09% -16.33% 301.92%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$2.500M -$2.798M -$1.876M
YoY Change 7.63% 49.11% 237.6%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$2.850M -$2.191M -$1.461M
YoY Change 42.55% 49.91% 19.13%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -70.00K 0.000 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -2.850M -2.191M -1.461M
Cash From Investing Activities
Cash From Financing Activities -70.00K 0.000 0.000
Net Change In Cash -2.920M -2.191M -1.461M
YoY Change 46.05% 49.91% -277.75%
FREE CASH FLOW
Cash From Operating Activities -$2.850M -$2.191M -$1.461M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
25633217 shares
CY2023Q1 us-gaap Cash
Cash
14164805 usd
dei Entity Central Index Key
EntityCentralIndexKey
0001815974
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
usd
us-gaap Payments For Repurchase Of Initial Public Offering
PaymentsForRepurchaseOfInitialPublicOffering
usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
CY2022Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
usd
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
pure
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
pure
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40388
dei Entity Registrant Name
EntityRegistrantName
ANEBULO PHARMACEUTICALS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-1170950
dei Entity Address Address Line1
EntityAddressAddressLine1
1415 Ranch Road 620 South
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 201
dei Entity Address City Or Town
EntityAddressCityOrTown
Lakeway
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
78734
dei City Area Code
CityAreaCode
(512)
dei Local Phone Number
LocalPhoneNumber
598-0931
dei Security12b Title
Security12bTitle
Common Stock
CY2022Q2 us-gaap Cash
Cash
14548471 usd
us-gaap Net Income Loss
NetIncomeLoss
-9236758 usd
us-gaap Net Income Loss
NetIncomeLoss
-4502877 usd
CY2023Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
267801 usd
CY2022Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1030960 usd
CY2023Q1 us-gaap Assets
Assets
14432606 usd
CY2022Q2 us-gaap Assets
Assets
15579431 usd
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
570902 usd
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
380828 usd
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
920183 usd
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
131703 usd
CY2023Q1 us-gaap Liabilities
Liabilities
1491085 usd
CY2022Q2 us-gaap Liabilities
Liabilities
512531 usd
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000 shares
dei Trading Symbol
TradingSymbol
ANEB
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000 shares
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000 shares
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25633217 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25633217 shares
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
23344567 shares
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
23344567 shares
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
25634 usd
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
23345 usd
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
67622348 usd
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
60513258 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-54706461 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-45469703 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
12941521 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
15066900 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14432606 usd
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15579431 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1089342 usd
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
915363 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4183038 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1843397 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1774699 usd
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
964281 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5106172 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2662293 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
2864041 usd
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
1879644 usd
us-gaap Operating Expenses
OperatingExpenses
9289210 usd
us-gaap Operating Expenses
OperatingExpenses
4505690 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2864041 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1879644 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-9289210 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-4505690 usd
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
66070 usd
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3153 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
52452 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2813 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2797971 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-1876491 usd
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25633217 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23344567 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24888916 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23344567 shares
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.08
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.37
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
21411858 usd
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
34173 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-1553395 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
19892636 usd
CY2021Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
94282 usd
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
-1072991 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
18913927 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
125254 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-1876491 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
17162690 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
15066900 usd
CY2022Q3 us-gaap Payments For Repurchase Of Initial Public Offering
PaymentsForRepurchaseOfInitialPublicOffering
248927 usd
CY2022Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
6397821 usd
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
52400 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
211900 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-2611835 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
19117186 usd
CY2022Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
225621 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-3826952 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
15515855 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
15515855 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
223637 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2797971 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
12941521 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
12941521 usd
us-gaap Net Income Loss
NetIncomeLoss
-9236758 usd
us-gaap Net Income Loss
NetIncomeLoss
-4502877 usd
us-gaap Share Based Compensation
ShareBasedCompensation
661158 usd
us-gaap Share Based Compensation
ShareBasedCompensation
253709 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-763159 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-967106 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
190074 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-26771 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
788480 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-129085 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6833887 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3437918 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
6646748 usd
us-gaap Payments For Repurchase Of Initial Public Offering
PaymentsForRepurchaseOfInitialPublicOffering
248927 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
52400 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6450221 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-383666 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3437918 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
14548471 usd
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
19985645 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
14164805 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
16547727 usd
us-gaap Net Income Loss
NetIncomeLoss
-9200000 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-54700000 usd
CY2023Q1 us-gaap Prepaid Insurance
PrepaidInsurance
78332 usd
CY2022Q2 us-gaap Prepaid Insurance
PrepaidInsurance
790343 usd
CY2023Q1 ANEB Prepaid Research And Development
PrepaidResearchAndDevelopment
142970 usd
CY2022Q2 ANEB Prepaid Research And Development
PrepaidResearchAndDevelopment
210865 usd
CY2023Q1 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
46499 usd
CY2022Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
29752 usd
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
267801 usd
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1030960 usd
CY2023Q1 ANEB Accrued Research And Development
AccruedResearchAndDevelopment
591434 usd
CY2022Q2 ANEB Accrued Research And Development
AccruedResearchAndDevelopment
105980 usd
CY2023Q1 us-gaap Other Employee Related Liabilities Current
OtherEmployeeRelatedLiabilitiesCurrent
297999 usd
CY2022Q2 us-gaap Other Employee Related Liabilities Current
OtherEmployeeRelatedLiabilitiesCurrent
25723 usd
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
30750 usd
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
920183 usd
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
131703 usd
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000 shares
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000 shares
CY2021Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y6M
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.500 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.50 pure
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1911459 shares
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.63
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y4M24D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
172654 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.31
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
24000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.18
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
10800 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
6.00
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2049313 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.54
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
415956 usd
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
661867 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.33
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P3Y4M24D
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
250815 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.86
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
2700000 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y10M24D
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
223637 usd
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
125254 usd
us-gaap Share Based Compensation
ShareBasedCompensation
661158 usd
us-gaap Share Based Compensation
ShareBasedCompensation
253709 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4313963 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1483833 shares

Files In Submission

Name View Source Status
0001493152-23-016382-index-headers.html Edgar Link pending
0001493152-23-016382-index.html Edgar Link pending
0001493152-23-016382.txt Edgar Link pending
0001493152-23-016382-xbrl.zip Edgar Link pending
aneb-20230331.xsd Edgar Link pending
aneb-20230331_def.xml Edgar Link unprocessable
aneb-20230331_cal.xml Edgar Link unprocessable
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
aneb-20230331_lab.xml Edgar Link unprocessable
aneb-20230331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed